trending Market Intelligence /marketintelligence/en/news-insights/trending/QIudGb-Z9GlsnvwMin2S5A2 content esgSubNav
In This List

ResTORbio plans $50M common stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


ResTORbio plans $50M common stock offering

Biopharmaceutical company resTORbio Inc. started an underwritten public offering of $50 million of its common shares.

Underwriters will have an option to buy up to an additional 15% of shares in the public offering to cover overallotments.

BofA Merrill Lynch, SVB Leerink and Guggenheim Securities are acting as joint book-running managers with Wedbush PacGrow acting as co-manager for the proposed offering.

Boston-based resTORbio develops and sells novel therapeutics to treat aging-related diseases.